VXS-1219 is under clinical development by Vaxxas and currently in Phase I for Influenza A Virus, H7N9 Subtype Infections. According to GlobalData, Phase I drugs for Influenza A Virus, H7N9 Subtype Infections does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the VXS-1219 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
VXS-1219 overview
VXS-1219 is under development for the prevention of influenza A (H7N9) virus infections. The vaccine candidate is administered through intradermal route as a patch. It is being developed based on high density micro array patch (HD-MAP) technology.
Vaxxas overview
Vaxxas is a biotechnology company that develops and commercializes novel technologies for enhancing the performance of existing and next-generation vaccines. It develops a microneedle array patch based on its proprietary High Density Microarray Patch (HD-MAP) technology, that creates a potent immune response by applying a patch to the skin for few seconds. Vaxxas is targeting applications in infectious diseases and oncology. The company operates in the US and Australia. Vaxxas is headquartered in Hamilton, Queensland, Australia.
For a complete picture of VXS-1219’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
